NBTX

26.5002.98%
AH

Alain Herrera

Independent Member of Supervisory Board

Dr. Alain Herrera, M.D., PhD, serves as an Independent Director of Isofol Medical AB (publ) since January 04, 2024 and previously served as its Independent Director since May 03, 2018 until February 2023. Dr. Herrera contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. He served as Head of Corporate Development and Managing Director of Pharmaengine Europe Sarl at PharmaEngine Inc. until 2019. Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital and Beaujon Hospital since 1991. He has more than two decades of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. He is Consultant in Oncology. He has created Alain Oncology Consulting (AOC) in November 2008. He served as a Senior Advisor of PharmaEngine Inc. since March 4, 2013. Dr. Herrera served as Vice President of Global Oncology Business Strategy and Development at Sanofi-aventis from 2007 to 2008 and Head of Global Oncology Franchise from 1998 to 2007. He serves as a Managing Director at ALAIN ONCOLOGIE CONSULTING and AB BIO CONSULTING. While at Sanofi-Aventis, he contributed to the worldwide registration of two products:Oxaliplatin (Eloxatin?) and Rasburicase (Fasturtec?/Elitek?), as well as the Gastric and Head& Neck indications for Docetaxel (Taxotere?). Before setting up his own oncology consultancy - Alain Oncologie Consulting (AOC), he Headed the Oncology business at Sanofi-Aventis for a decade. He contributed to the worldwide registration of Oxaliplatin (Eloxatin(R)) and Rasburicase (Fasturtec(R)/Elitek(R)), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere(R)). He was Corporate Vice President and Member of Management Council of Chiron Corporation. His previous responsibilities within the pharmaceutical industry included the roles of Managing Director at Pierre Fabre Oncology Laboratories, Head of the Oncology Platform at Roger Bellon (Rh ne Poulenc) and served as Chairman of Chiron Therapeutics Europe. Dr. Herrera serves as Non-Executive Director of International Drug Development Institute SA and PDC line Pharma SAS. He had been a Member of Scientific Advisory Board at PharmaEngine Inc. from November 2008 to 2019. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation. He has been Independent Member of Supervisory Board at Nanobiotix SA since June 28, 2013. He served as Director of Chiron B.V. He also used to be Senior Resident, assistant to Prof. Pierre Boivin (Beaujon Hospital/University Paris VII). Dr. Herrera has published and lectured extensively as an invited speaker at national and international meetings on cancers. He has authored numerous manuscripts and contributing to numerous review articles and book chapters. He is an active Member of ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology).

Positions